VRTX Revenue 2026
Annual and quarterly sales data for Vertex Pharmaceuticals Inc
Latest Annual Revenue
$11.02B
2024-12-31
YoY Growth
+11.7%
vs. previous year
4-Year CAGR
61.3%
compound growth
Annual Revenue History
2024-12-31
$11.02B
YoY Growth
+11.7%
2023-12-31
$9.87B
YoY Growth
+10.5%
2022-12-31
$8.93B
YoY Growth
+17.9%
2021-12-31
$7.57B
YoY Growth
+365.3%
2020-12-31
$1.63B
Quarterly Revenue Breakdown
2025-09-30
$3.08B
2025-06-30
$2.96B
2025-03-31
$2.77B
2024-09-30
$2.77B
2024-06-30
$2.65B
2024-03-31
$2.69B
2023-09-30
$2.48B
2023-06-30
$2.49B
Revenue by Segment
Get Full VRTX Financial Analysis
View complete income statements, balance sheets, and AI-powered insights
Frequently Asked Questions
What is VRTX's revenue?
VRTX (Vertex Pharmaceuticals Inc) reported $11.02 billion in revenue for 2024-12-31. This represents a 11.7% increase compared to the previous year.
How much revenue does VRTX make per year?
Vertex Pharmaceuticals Inc generates approximately $11.02 billion in annual revenue based on the most recent fiscal year ending 2024-12-31.
Is VRTX revenue growing?
Yes, VRTX's revenue is growing. The company achieved 11.7% revenue growth year-over-year. Over the past 4 years, revenue has grown at a compound annual growth rate (CAGR) of 61.3%.
What is VRTX's quarterly revenue?
VRTX reported $3.08 billion in revenue for the most recent quarter (2025-09-30). This is 3.8% higher than the previous quarter.
What are VRTX's revenue sources?
VRTX's revenue comes from multiple segments: Total Revenue. See the revenue breakdown below for detailed segment analysis.
How does VRTX compare to competitors in revenue?
VRTX generates $11.02 billion in annual revenue in the Health Care sector. Compare VRTX to competitors using our stock comparison tool to see relative market share and growth rates.
Disclaimer: Revenue data is based on publicly filed financial statements. Historical performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.